HETEROCYCLIC AMIDE DERIVATIVE AND MEDICINE CONTAINING SAME

1 . A medicament, comprising a compound represented by formula (I):

wherein:

Ar is a C 6-10 aryl group optionally having 1-4 substituents or a C 1-9 heteroaryl group optionally having 1-4 substituents;

Y is —C(Ry1)(Ry2)-, or a single bond;

Z is —C(Rz1)(Rz2)-, an oxygen atom, a sulfur atom, or a single bond;

n is 0 or 1;

m is 0 or 1;

provided n+m≦1;

partial structure (1)

is a phenylene group optionally having 1-4 substituents, or a divalent group of a 5-membered or 6-membered heteroaromatic ring containing 1-3 hetero atoms selected from oxygen atom, nitrogen atom, and sulfur atom and optionally having 1-3 substituents;

partial structure (2)

is a C 6-10 aryl group optionally having 1-4 substituents or a C 1-9 heteroaryl group optionally having 1-4 substituents;

R 1 is a hydrogen atom, a C 1-6 alkyl group, a C 2-6 alkenyl group, a C 2-6 alkynyl group, a halogeno C 1-6 alkyl group, a cyclic C 3-6 alkyl group, or a C 1-6 alkyl group substituted by cyclic C 3-6 alkyl group;

R 2 and R 3 are the same or different and each is a hydrogen atom, a C 1-6 alkyl group, a C 2-6 alkenyl group, or a C 2-6 alkynyl group;

R 4 through R 8 , Ry1, Ry2, Rz1, and Rz2 are the same or different and each is a hydrogen atom, a C 1-6 alkyl group, a C 2-6 alkenyl group, a C 2-6 alkynyl group, a halogeno C 1-6 alkyl group, a C 1-6 alkoxy group, a hydroxyl group, a halogeno C 1-6 alkoxy group, an amino group, an amino group mono- or di-substituted by a C 1-6 alkyl group, or a halogeno group; or

any of R 4 through R 8 , Ry1, Ry2, Rz1, or Rz2 which are bonded to adjacent carbon atoms are optionally joined to form a double bond and/or a ring; or

any of R 5 and R 6 , R 7 and R 8 , Ry1 and Ry2, or Rz1 and Rz2 which are bonded to the same carbon atom are optionally joined to form a ring;

Rx1 through Rx4 are the same or different and each is a hydrogen atom, a C 1-6 alkyl group, a C 2-6 alkenyl group, a C 2-6 alkynyl group, a C 1-6 alkyl group substituted by a hydroxyl group, a C 1-6 alkyl group substituted by an amino group, or a C 1-6 alkyl group substituted by an amino group mono- or di-substituted by a C 1-6 alkyl group; or

any of Rx1 and Rx2, or Rx3 and Rx4 which are bonded to the same carbon atom are optionally joined to form a ring,

or a pharmaceutically acceptable salt thereof.

2 . A medicament according to claim 1 , wherein Y and/or Z are/is a single bond.

3 . A medicament according to claim 1 , wherein:

Ar is a phenyl group optionally having 1 or 2 substituents or a 5- or 6-membered monocyclic heteroaryl group optionally having 1 or 2 substituents.

4 . A medicament according to claim 1 , wherein:

partial structure (1) is either a phenylene group optionally having 1-3 substituents, or a divalent group of a pyridine ring optionally having 1-3 substituents.

5 . A medicament according to claim 1 , wherein:

partial structure (1) is

wherein Ra 1 is a hydrogen atom or a substituent.

6 . A medicament according to claim 1 , wherein

partial structure (2) is a phenyl group optionally having 1-3 substituents, or a pyridyl group, a quinolyl group or an isoquinolyl group, each of which optionally has 1-3 substituents.

7 . A medicament according to claim 1 , wherein:

n=0.

8 . A medicament according to claim 1 , wherein:

R 2 and R 3 are each a hydrogen atom.

9 . A medicament according to claim 1 , wherein:

partial structure (2) is a phenyl group optionally having a substituent or a pyridyl group optionally having a substituent.

10 . A medicament according to claim 1 , which is a TRPA1 antagonist.

11 . A method for the prophylaxis and/or treatment of a disease involving TRPA1, comprising administering to a subject in need thereof an effective amount of a medicament according to claim 10 .

12 . A method according to claim 11 , wherein said disease involving TRPA1 is selected from the group consisting of a pain associated disease, an inflammatory disease, a digestive tract disease, a lung disease, a bladder disease, a dermatologic disease, and a neurological disease.

13 . A method according to claim 11 , wherein said disease involving TRPA1 is selected from the group consisting of chronic pain, acute pain, asthma, chronic obstructive pulmonary disease, functional gastrointestinal disorder, erosive esophagitis, inflammatory bowel disease, and pruritus.

14 . A compound represented by formula (IA):

wherein:

Ar is a C 6-10 aryl group optionally having 1-4 substituents or a C 1-9 heteroaryl group optionally having 1-4 substituents;

Y is —C(Ry1)(Ry2)-, or a single bond;

Z is —C(Rz1)(Rz2)-, an oxygen atom, a sulfur atom, or a single bond;

n is 0 or 1;

m is 0 or 1;

provided n+m≦1;

partial structure (1)

is a phenylene group optionally having 1-4 substituents, or a divalent group of a 5-membered or 6-membered heteroaromatic ring containing 1-3 hetero atoms selected from oxygen atom, nitrogen atom, and sulfur atom and optionally having 1-3 substituents;

partial structure (2)

is a C 6-10 aryl group optionally having 1-4 substituents or a C 1-9 heteroaryl group optionally having 1-4 substituents;

R 1 is a hydrogen atom, a C 1-6 alkyl group, a C 2-6 alkenyl group, a C 2-6 alkynyl group, a halogeno C 1-6 alkyl group, a cyclic C 3-6 alkyl group, or a C 1-6 alkyl group substituted by a cyclic C 3-6 alkyl group;

R 2 and R 3 are the same or different and each is a hydrogen atom, a C 1-6 alkyl group, a C 2-6 alkenyl group, or a C 2-6 alkynyl group;

R 4 through R 8 , Ry1, Ry2, Rz1 and Rz2 are the same or different and each is a hydrogen atom, a C 1-6 alkyl group, a C 2-6 alkenyl group, a C 2-6 alkynyl group, a halogeno C 1-6 alkyl group, a C 1-6 alkoxy group, a hydroxyl group, a halogeno C 1-6 alkoxy group, an amino group, an amino group mono- or di-substituted by a C 1-6 alkyl group, or a halogeno group; or

any of R 4 through R 8 , Ry1, Ry2, Rz1 or Rz2 which are bonded to adjacent carbon atoms are optionally joined to form a double bond and/or a ring; or

any of R 5 and R 6 , R 7 and R 8 , Ry1 and Ry2, or Rz1 and Rz2 which are bonded to the same carbon atom are optionally joined to form a ring;

Rx1 through Rx4 are the same or different and each is a hydrogen atom, a C 1-6 alkyl group, a C 2-6 alkenyl group, a C 2-6 alkynyl group, a C 1-6 alkyl group substituted by a hydroxyl group, a C 1-6 alkyl group substituted by an amino group, or a C 1-6 alkyl group substituted by an amino group mono- or di-substituted by a C 1-6 alkyl group; or

any of Rx1 and Rx2, or Rx3 and Rx4 which are bonded to the same carbon atom are optionally joined to form a ring,

or a pharmaceutically acceptable salt thereof,

excluding the following compounds:

N-[[2-(2-fluorophenoxyl)phenyl]methyl]-1-(2-thienylsulfonyl)pyrrolidine-2-carboxamide;

ethyl 5-[[2-[[[(2-phenoxyphenyl)methyl]amino]carbonyl]-1-pyrrolidinyl]sulfonyl]-2-furancarboxylate;

N-[[3-fluoro-4-(3-pyridinyloxyl)phenyl]methyl]-1-(phenylsulfonyl)-pyrrolidine-2-carboxamide;

N-[(3-phenoxyphenyl)methyl]-1-(2-thienylsulfonyl)-pyrrolidine-2-carboxamide;

N-[(2-phenoxyphenyl)methyl]-1-(2-thienylsulfonyl)-pyrrolidine-2-carboxamide;

N-[[6-(2,5-dimethylphenoxy)-3-pyridinyl]methyl]-1-(phenylsulfonyl)-pyrrolidine-2-carboxamide;

N-[[2-(4-fluorophenoxy)-4-pyridinyl]methyl]-1-(phenylsulfonyl)-pyrrolidine-2-carboxamide;

N-[[6-(3-fluorophenoxy)-3-pyridinyl]methyl]-1-(phenylsulfonyl)-pyrrolidine-2-carboxamide;

1-(phenylsulfonyl)-N-[[3-(2-pyridinylmethoxy)-phenyl]methyl]-pyrrolidine-2-carboxamide;

(2S)-1-[(4-methylphenyl)sulfonyl]-N-[[2-(phenylmethoxy)-4-pyridinyl]methyl]-pyrrolidine-2-carboxamide;

1-[(4-fluorophenyl)sulfonyl]-N-[[6-(4-methoxyphenoxy)-3-pyridinyl]methyl]-pyrrolidine-2-carboxamide;

1-[(4-fluorophenyl)sulfonyl]-N-[[3-methoxy-4-(3-pyridinylmethoxy)phenyl]methyl]-pyrrolidine-2-carboxamide;

N-[1-[4-(3-pyridinylmethoxy)phenyl]ethyl]-1-(2-thienylsulfonyl)-pyrrolidine-2-carboxamide;

N-[[2-(phenylmethoxy)phenyl]methyl]-1-(2-thienylsulfonyl)-pyrrolidine-2-carboxamide;

1-[(4-fluorophenyl)sulfonyl]-N-[[3-methoxy-4-(phenylmethoxy)phenyl]methyl]-pyrrolidine-2-carboxamide;

N-[[2-(phenylmethoxy)phenyl]methyl]-1-(2-thienylsulfonyl)-pyrrolidine-2-carboxamide;

N-[[6-(4-fluorophenoxy)-3-pyridinyl]methyl]-1-(2-thienylsulfonyl)-pyrrolidine-2-carboxamide;

1-[(4-fluorophenyl)sulfonyl]-N-[1-[3-(2-pyridinylmethoxy)phenyl]ethyl]-pyrrolidine-2-carboxamide;

N-[[4-(phenoxymethyl)phenyl]methyl]-1-(2-thienylsulfonyl)-pyrrolidine-2-carboxamide;

N-[[3-(phenylmethoxy)phenyl]methyl]-1-(2-thienylsulfonyl)-pyrrolidine-2-carboxamide;

1-[(4-fluorophenyl)sulfonyl]-N-[[4-(3-pyridinylmethoxy)phenyl]methyl]-pyrrolidine-2-carboxamide;

1-[(4-fluorophenyl)sulfonyl]-N-[[2-(phenylmethoxy)-4-pyridinyl]methyl]-pyrrolidine-2-carboxamide;

N-[[3-(2-pyridinylmethoxy)phenyl]methyl]-1-[(2,4,6-trimethylphenyl)sulfonyl]-pyrrolidine-2-carboxamide;

1-(phenylsulfonyl)-N-[[3-(2-pyridinylmethoxy)phenyl]methyl]-pyrrolidine-2-carboxamide;

N-[[2-(phenylmethoxy)-4-pyridinyl]methyl]-1-(2-thienylsulfonyl)-pyrrolidine-2-carboxamide;

N-[[6-(2,5-dimethylphenoxy)-3-pyridinyl]methyl]-1-(2-thienylsulfonyl)-2-piperidinecarboxamide;

N-[[2-(phenoxymethyl)phenyl]methyl]-1-(2-thienylsulfonyl)-pyrrolidine-2-carboxamide;

1-[(4-fluorophenyl)sulfonyl]-N-[[3-(phenylmethoxy)phenyl]methyl]-pyrrolidine-2-carboxamide;

1-[(4-fluorophenyl)sulfonyl]-N-[[3-fluoro-4-(3-pyridinyloxyl)phenyl]methyl]-pyrrolidine-2-carboxamide;

N-[[3-methoxy-4-(4-pyridinylmethoxy)phenyl]methyl]-1-(phenylsulfonyl)-pyrrolidine-2-carboxamide;

(2S)-1-[(4-methylphenyl)sulfonyl]-N-[1-[3-(2-pyridinylmethoxy)phenyl]ethyl]-pyrrolidine-2-carboxamide;

1-[(3,4-dimethoxyphenyl)sulfonyl]-N-[(3-phenoxyphenyl)methyl]-pyrrolidine-2-carboxamide;

N-[1-[3-methoxy-4-(4-pyridinylmethoxy)phenyl]ethyl]-1-(phenylsulfonyl)-pyrrolidine-2-carboxamide;

2-[(3,4-dimethoxyphenyl)sulfonyl]-1,2,3,4-tetrahydro-N-[(3-phenoxyphenyl)methyl]-isoquinoline-3-carboxamide;

(2S)-1-[(3,5-dimethyl-4-isoxazolyl)sulfonyl]-N-[[4-(4-fluorophenoxyl)phenyl]methyl]-pyrrolidine-2-carboxamide;

1,2,3,4-tetrahydro-2-[(4-methylphenyl)sulfonyl]-N-[(3-phenoxyphenyl)methyl]-isoquinoline-3-carboxamide;

(2S)—N-[[3-methoxy-4-(4-pyridylmethoxy)phenyl]methyl]-1-(p-tolylsulfonyl)pyrrolidine-2-carboxamide;

(2S)—N-[(4-benzyloxy-3-methoxy-phenyl)methyl]-1-(p-tolylsulfonyl)pyrrolidine-2-carboxamide;

(2S)-1-(4-fluorophenyl) sulfonyl-N-[[3-(2-pyridylmethoxy)phenyl]methyl]pyrrolidine-2-carboxamide;

(2S)—N-[[6-(2-ethoxyphenoxy)-3-pyridyl]methyl]-1-(p-tolylsulfonyl)pyrrolidine-2-carboxamide;

N-[[6-(2,5-dimethylphenoxy)-3-pyridyl]methyl]-1-(4-fluorophenyl)sulfonyl-pyrrolidine-2-carboxamide; and

N-[[6-(4-fluorophenoxy)-3-pyridyl]methyl]-1-(4-fluorophenyl) sulfonyl-pyrrolidine-2-carboxamide.

15 . A compound or pharmaceutically acceptable salt according to claim 14 , wherein Y and/or Z are/is a single bond.

16 . A compound or pharmaceutically acceptable salt according to claim 14 , wherein:

Ar is a phenyl group optionally having 1 or 2 substituents or a 5- or 6-membered monocyclic heteroaryl group optionally having 1 or 2 substituents.

17 . A compound or pharmaceutically acceptable salt according to claim 14 , wherein:

partial structure (1) is either a phenylene group optionally having 1-3 substituents, or a divalent group of a pyridine ring optionally having 1-3 substituents.

18 . A compound or pharmaceutically acceptable salt according to claim 14 , wherein:

partial structure (1) is

wherein Ra 1 is a hydrogen atom or a substituent.

19 . A compound or pharmaceutically acceptable salt according to claim 14 , wherein:

partial structure (2) is a phenyl group optionally having 1-3 substituents, or a pyridyl group, a quinolyl group or an isoquinolyl group, each of which optionally has 1-3 substituents.

20 . A compound or pharmaceutically acceptable salt according to claim 14 , wherein:

n=0.

21 . A compound or pharmaceutically acceptable salt according to claim 14 , wherein:

R 2 and R 3 are each a hydrogen atom.

22 . A compound or pharmaceutically acceptable salt according to claim 14 , wherein:

partial structure (2) is a phenyl group optionally having a substituent or a pyridyl group optionally having a substituent.

23 . A method for the prophylaxis and/or treatment of a disease involving TRPA1, comprising administering to a subject in need thereof an effective amount of a compound or pharmaceutically acceptable salt according to claim 14 .

24 . A method according to claim 23 , wherein said disease involving TRPA1 is selected from the group consisting of a pain associated disease, an inflammatory disease, a digestive tract disease, a lung disease, a bladder disease, a dermatologic disease, and a neurological disease.

25 . A method according to claim 23 , wherein said disease involving TRPA1 is selected from the group consisting of chronic pain, acute pain, asthma, chronic obstructive pulmonary disease, functional gastrointestinal disorder, erosive esophagitis, inflammatory bowel disease, and pruritus.